【摘要】 目的 探讨经导管动脉灌注化疗（TAI）联合碘化油化疗栓塞治疗晚期结直肠癌（CRC）的安全性、可行性及有效性。方法 回顾性分析2016年6月至2022年12月郑州大学第一附属医院收治的37例接受TAI联合碘化油化疗栓塞治疗的晚期CRC患者临床资料。评价其疗效，记录无疾病进展生存期（PFS），观察有无严重并发症发生。结果 37例患者共成功接受55次TAI和碘化油化疗栓塞治疗，均获得成功。碘化油乳剂使用剂量为2.9 mL(0.8～10 mL)。无出血、肠穿孔等严重并发症发生。中位随访时间为24个月（3～48个月），术后1、3、6、12个月客观缓解率（ORR）分别为67.6%(25/37)、67.6%(25/37)、64.9%(24/37)、56.8%(21/37)，疾病控制率（DCR）分别为91.9%(34/37)、91.9%(34/37)、89.2%(33/37)、81.1%(30/37)。中位PFS为16个月（2～47个月）。截至末次随访，22例患者生存，15例患者死于肿瘤终末期。结论 初步证明TAI联合碘化油化疗栓塞治疗晚期CRC安全有效，为晚期CRC患者提供了一种新治疗手段。更多还原

【Abstract】 Objective To discuss the clinical safety, feasibility and efficacy of transcatheter arterial infusion chemotherapy(TAI) combined with lipiodol chemoembolization in the treatment of advanced colorectal cancer(CRC). Methods The clinical data of 37 patients with advanced CRC, who received TAI combined with lipiodol chemoembolization at the First Affiliated Hospital of Zhengzhou University of China between June2016 and December 2022, were retrospectively analyzed. The clinical efficacy was evaluated, the progressionfree survival(PFS) and the serious complications were recorded. Results A total of 55 times of TAI combined with lipiodol chemoembolization procedures were successfully accomplished in the 37 patients. The mean used amount of lipiodol emulsion was 2.9 mL(0.8-10 mL). No serious complications such as bleeding and intestinal perforation occurred. The median follow-up time was 24 months(range of 3-48 months). The postoperative one-month, 3-month, 6-month and 12-month objective remission rates(ORR) were 67.6%(25/37), 67.6%(25/37), 64.9%(24/37) and 56.8%(21/37) respectively, and the postoperative one-month, 3-month, 6-month and 12-month disease control rates(DCR) were 91.9%(34/37), 91.9%(34/37), 89.2%(33/37) and 81.1%(30/37)respectively. The median PFS was 16 months(range of 2-47 months). As of the last follow-up, 22 patients survived and 15 patients died of terminal stage of tumor. Conclusion Preliminary results of this study indicate that TAI combined with lipiodol chemoembolization is clinically safe and effective for advanced CRC, and it provide a new therapeutic method for patients with advanced CRC.(J Intervent Radiol, 2024, 32: 186-190)更多还原